SecSonar.com

Genmab A/S (GMAB)

Genmab A/S at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Genmab A/S (GMAB) is a Biotechnology company based in DK with a market capitalization of $16.3B. Revenue declined 82.7% year-over-year and the company generated $1.1B in free cash flow. This page tracks GMAB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

DK · 2.64K employees · IPO Jun 1, 2009

Valuation

Valuation & price

$26.88 · as of May 26, 2026 · -24.0% vs 52w high

17.5

P/E ratio

Latest-FY diluted EPS

2.79

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$35.34$27.93$20.52Jul 25Dec 25Jul 26Jul 7, 25$20.52Jul 9, 25$21.58Jul 11, 25$21.40Jul 15, 25$21.15Jul 17, 25$22.01Jul 21, 25$21.69Jul 23, 25$22.87Jul 25, 25$23.40Jul 29, 25$22.60Jul 31, 25$21.67Aug 4, 25$21.98Aug 6, 25$21.51Aug 11, 25$21.08Aug 13, 25$22.67Aug 15, 25$23.31Aug 19, 25$23.82Aug 21, 25$24.42Aug 25, 25$24.31Aug 27, 25$24.78Aug 29, 25$24.87Sep 3, 25$27.08Sep 5, 25$27.54Sep 9, 25$27.83Sep 11, 25$28.61Sep 16, 25$28.24Sep 18, 25$28.04Sep 22, 25$28.60Sep 24, 25$29.45Sep 26, 25$29.07Sep 30, 25$30.67Oct 2, 25$32.12Oct 6, 25$33.31Oct 8, 25$32.74Oct 10, 25$31.81Oct 14, 25$32.75Oct 16, 25$32.75Oct 21, 25$30.13Oct 23, 25$29.87Oct 27, 25$29.03Oct 29, 25$28.95Oct 31, 25$28.61Nov 4, 25$28.76Nov 6, 25$28.84Nov 10, 25$29.06Nov 12, 25$30.47Nov 14, 25$30.26Nov 18, 25$30.32Nov 20, 25$30.04Nov 25, 25$31.40Nov 28, 25$32.36Dec 2, 25$31.71Dec 4, 25$32.02Dec 8, 25$31.94Dec 10, 25$31.24Dec 12, 25$31.31Dec 16, 25$31.35Dec 18, 25$31.50Dec 22, 25$33.06Dec 24, 25$33.72Dec 29, 25$32.52Jan 2, 26$31.82Jan 6, 26$33.10Jan 8, 26$33.63Jan 12, 26$33.95Jan 14, 26$35.34Jan 16, 26$32.25Jan 21, 26$32.95Jan 23, 26$33.88Jan 27, 26$34.40Jan 29, 26$33.35Feb 2, 26$33.27Feb 4, 26$31.90Feb 9, 26$30.87Feb 11, 26$30.06Feb 13, 26$30.03Feb 18, 26$29.16Feb 20, 26$29.29Feb 24, 26$29.40Feb 26, 26$29.24Mar 2, 26$29.65Mar 4, 26$28.18Mar 6, 26$27.06Mar 10, 26$27.96Mar 12, 26$26.57Mar 17, 26$26.36Mar 19, 26$25.73Mar 23, 26$25.68Mar 25, 26$26.11Mar 27, 26$25.82Mar 31, 26$26.83Apr 2, 26$27.50Apr 7, 26$27.65Apr 9, 26$28.28Apr 13, 26$28.20Apr 15, 26$29.30Apr 17, 26$28.55Apr 22, 26$27.69Apr 24, 26$26.87Apr 28, 26$26.79Apr 30, 26$26.52May 4, 26$27.04May 6, 26$27.89May 8, 26$26.43May 12, 26$27.09May 14, 26$26.90May 18, 26$26.37May 20, 26$27.21May 22, 26$26.87May 28, 26$27.04Jun 1, 26$25.45Jun 3, 26$23.88Jun 5, 26$25.15Jun 9, 26$25.10Jun 11, 26$25.24Jun 15, 26$24.58Jun 17, 26$25.39Jun 22, 26$25.61Jun 24, 26$25.87Jun 26, 26$26.12Jul 2, 26$28.52
$20.5252-week range$35.34
Loading valuation history…

Fundamentals

Key fundamentals

$16.3B

Market cap

-82.7%

Revenue growth (YoY)

91.7%

Gross margin

$1.1B

Free cash flow (USD)

$3.7B

Net debt

-3.8%

Share dilution

5/6

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.8BFY 2017$2.4BFY 2018$3.0BFY 2019$5.4BFY 2020$10.1BFY 2021$8.4BFY 2022$14.5BFY 2023$16.5BFY 2024$21.5BFY 2025$3.7B
$1.8B$3.7B

Free cash flow by year

2016 → 2025

FY 2016$294.6MFY 2017$1.5BFY 2018$537.4MFY 2019$1.2BFY 2020$6.1BFY 2021$2.0BFY 2022$3.6BFY 2023$7.0BFY 2024$7.6BFY 2025$1.1B
$294.6M$1.1B

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 202398.6%FY 202495.4%FY 202591.7%
100.0%91.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingPositive Phase 3 ResultsJun 29, 2026Filing
  • 6-K filingArticles of AssociationJun 17, 2026Filing
  • 6-K filingCapital IncreaseJun 16, 2026Filing
  • 6-K filingArticles of AssociationJun 15, 2026Filing
  • 6-K filingMajor Shareholder AnnouncementJun 15, 2026Filing
  • 6-K filingGrant of Stock Units and WarrantsJun 11, 2026Filing
  • 6-K filingTransactions by Managerial EmployeesMay 29, 2026Filing
  • 6-K filingArticles of AssociationMay 13, 2026Filing
  • 6-K filingCapital IncreaseMay 12, 2026Filing
  • 6-K filingMajor Shareholder AnnouncementMay 8, 2026Filing

Questions

Frequently asked questions

What is Genmab A/S's market cap?

Genmab A/S (GMAB) has a market capitalization of $16.3B.

What is GMAB's P/E ratio?

GMAB trades at a price-to-earnings ratio of 17.5, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is GMAB's price-to-book (P/B) ratio?

GMAB trades at 2.79 times book value per share.

Are insiders buying GMAB stock?

SEC Form 4 filings show no open-market insider buys at Genmab A/S in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

NBIX

Neurocrine Biosciences, Inc.

$15.9B

JAZZ

Jazz Pharmaceuticals plc

$14.6B

ASND

Ascendis Pharma A/S

$13.7B

MRNA

Moderna, Inc.

$19.3B

BBIO

BridgeBio Pharma, Inc.

$13.2B

INCY

Incyte Corporation

$19.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.